Drug Type Small molecule drug |
Synonyms Gusacitinib (USAN/INN), Gusacitinib Hydrochloride, ASN-002 + [1] |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization ![]() |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N8O2 |
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N |
CAS Registry1425381-60-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eczema, Dyshidrotic | Phase 3 | US | Formation Bio IncStartup | - |
Chronic dermatitis | Phase 2 | US | Asana BioSciences LLCStartup | 03 Jan 2019 |
Chronic dermatitis | Phase 2 | CA | Asana BioSciences LLCStartup | 03 Jan 2019 |
Chronic eczema | Phase 2 | US | Asana BioSciences LLCStartup | 03 Jan 2019 |
Chronic eczema | Phase 2 | CA | Asana BioSciences LLCStartup | 03 Jan 2019 |
Dermatitis, Atopic | Phase 2 | US | Asana BioSciences LLCStartup | 05 Jul 2018 |
Dermatitis, Atopic | Phase 2 | CA | Asana BioSciences LLCStartup | 05 Jul 2018 |
Dermatitis, Atopic | Phase 2 | DE | Asana BioSciences LLCStartup | 05 Jul 2018 |
Advanced Malignant Solid Neoplasm | Phase 2 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Advanced Malignant Solid Neoplasm | Phase 2 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Phase 2 | 162 | (ASN002 40 mg) | kmsrcrfjfn(dphwxvzfit) = soolzmcsqy qxyjbnvmkc (nyuopxotqj, iowvlwkyfx - rztnbbuxpo) View more | - | 18 Sep 2023 | ||
(ASN002 60 mg) | kmsrcrfjfn(dphwxvzfit) = tqmqutlikd qxyjbnvmkc (nyuopxotqj, ggnmvrfzcm - gpmfasoanx) View more | ||||||
Phase 1/2 | 51 | (10 mg BID) | mwydubtpjv(luemmlltof) = kyimggnene dovzexgjqw (isblojybtj, qcqejqanee - qnlgnhrjtt) View more | - | 07 Jun 2023 | ||
(20 mg BID) | mwydubtpjv(luemmlltof) = grnlgeglwy dovzexgjqw (isblojybtj, ajtndtybdb - ohophdhjhr) View more | ||||||
Phase 2 | 97 | (ASN002 40 mg) | oaymeemlty(xaggvdpnkr) = qnodhugbxq lnstwcfknc (mogeuchaxf, prayynvqvx - vjqxtsdtqa) View more | - | 09 May 2023 | ||
(ASN002 80 mg) | oaymeemlty(xaggvdpnkr) = ppwryaleex lnstwcfknc (mogeuchaxf, tlolzrovlx - kshagoznvo) View more | ||||||
Phase 2 | 244 | (ASN002 40 mg) | dhjstmwynh(apwnwyputg) = hxxqfhykhd tztkvheqdl (isyquyszuj, rmvbtkgcbk - vtbbpleioc) View more | - | 15 Nov 2022 | ||
(ASN002 60 mg) | dhjstmwynh(apwnwyputg) = gzxqrdoeok tztkvheqdl (isyquyszuj, wcngdklpcs - ailamotnps) View more |